Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 6/20 | 0.47 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9682608 | 0.87 | CYP2D6 (0.45) | SCN9ASCN7ASCN5ACYP2D6CHRM2 | |
| SCHEMBL1121776 | 0.83 | SCN9A (0.41) | SCN9ASCN7ASCN5ACYP2D6CYP3A4 | |
| SCHEMBL24809013 | 0.80 | CYP2D6 (0.46) | SCN9ASCN7ASCN5ACYP2D6CYP3A4 | |
| SCHEMBL85215 | 0.80 | OPRM1 (0.44) | SCN9ASCN7ASCN5ACYP2D6CYP3A4 | |
| SCHEMBL70441 | 0.77 | CYP2D6 (0.46) | SCN9ACYP2D6CYP3A4ALOX15SLC6A9 | |
| SCHEMBL16448465 | 0.76 | OPRM1 (0.41) | SCN9ASCN7ASCN5ACYP2D6SLC6A9 | |
| SCHEMBL13073743 | 0.76 | SLC6A9 (0.43) | SCN9ASCN7ASCN5ACYP2D6SLC6A9 | |
| SCHEMBL16759363 | 0.76 | SLC6A9 (0.46) | CYP2D6SLC6A9CHRM2CHRM4CHRM5 | |
| SCHEMBL10809151 | 0.75 | OPRM1 (0.41) | SCN7ASCN5ACYP2D6CYP3A4ALOX15 | |
| SCHEMBL2031016 | 0.74 | CYP2D6 (0.49) | CYP2D6CYP3A4ALOX15SLC6A9CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2018108954-A1 | PROCESS FOR THE PREPARATION OF 2-(3-(FLUOROMETHYL)AZETIDIN-1-YL)ETHAN-1-OL | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018108954-A1 | PROCESS FOR THE PREPARATION OF 2-(3-(FLUOROMETHYL)AZETIDIN-1-YL)ETHAN-1-OL | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-28 | — | — | US | disclosed |
| US-7135479-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| US-7094777-B2 | 5-HT2A receptor ligands | MERK SHARP & DOHME LTD. | 2006-08-22 | — | — | US | disclosed |
| EP-1685100-A1 | NOVEL 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS | Merck Sharp & Dohme Limited (GB) | 2006-08-02 | — | — | EP | disclosed |
| EP-1537119-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005047247-A1 | NOVEL1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047246-A1 | NOVEL 1, 3-DISUBSTITUTED AZETIDINE DEIVATIVES FOR USE AS 5HT2A RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101586-A1 | Novel 5-HT2A receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2005-05-12 | — | — | US | disclosed |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-08 | — | — | US | disclosed |
| WO-2004024730-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101586-A1 | Novel 5-HT2A receptor ligands | HTR2A, HTR1A, HTR5A | SCN9A 395/4885SCN7A 376/4885SCN5A 168/4885 |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, HTR5A, DBH | SCN9A 1506/4885SCN7A 1268/4885SCN5A 339/4885 |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CYP19A1, CRH, CYP17A1 | SCN9A 973/4885SCN7A 776/4885SCN5A 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.